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Abstract
The confusion centered around appropriate use of the CPT billing code 88172 is addressed in the 
commentary from the Economic and Government Affairs Committee of the American Society of 
Cytopathology (ASC) who have written a timely commentary in this issue of Cytojournal, “Adequate 
Reimbursement is Crucial to Support Cost-Effective Rapid Onsite Cytopathology Evaluations”. 
Currently, lack of standardized use within and between pathology departments is stirring unhealthy 
practices of denying reimbursements for this critical and legitimate cytopathology service. This 
editorial discusses the important concerns raised in this commentary and recommends immediate 
corrective action.  (See also Al-Abbadi MA, et al. Adequate reimbursement is crucial to support 
cost-effective rapid on-site cytopathology evaluations. CytoJournal 2010;7:22)
Key words: CPT, FNA, Biospy, on site adequacy evaluation, 88172, Cytology, cytopathology
In response to confusion centered around appropriate use 
of the CPT billing code 88172 pertaining to immediate 
cytological evaluation, Al-Abaddi, et al. of the Economic 
and Government Affairs Committee of the ASC have 
written a timely commentary in this issue of Cytojournal, 
“Adequate Reimbursement is Crucial to Support Cost-
Effective Rapid Onsite Cytopathology Evaluations”.[1] 
The October 2009 publication of the National Coding 
Corrective action policy manual,[2] attempting to clarify 
the parameters surrounding the appropriate use of the 
88172 fee code, has been met with a lack of standardized 
use within and between pathology departments, and 
reimbursements for legitimate pathology services have 
reportedly been denied. Multiple important points are 
raised in this commentary.[1]
Application of CPT code 88172 was reported in the 
September, 2006 issue of CAP Today, where specifics 
were addressed on when and how to use the code. It 
was stated that code 88172 may be used as many times 
as a pathologist is asked to assess adequacy, but each 
application of the fee code requires proper documentation 
of each interpretation in the report.[3] However, lack 
of well-defined guidelines has allowed some carriers 
to deny appropriate reimbursement for these codes 
and the time-consuming service provided. Adequacy 
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evaluation.[7] Wang et al., addressing the cost effectiveness 
of adequacy assessment with respect to thyroid FNAs,[9] 
reported that assessment increases the diagnostic yield 
of thyroid FNAs but at a tremendous expense to cytology 
service in time.[9]
At Wayne State University Hospitals, there is a fee code 
for each pass which is billed on separate lines using the 
modifier 26/76. However, reimbursement using modifier 
26/76 in the current environment is unpredictable, as 
experienced by a few institutions with some insurance 
carriers, and periodically shared at discussions in the 
ASC listserv. Interestingly, some payers state that only 
one 88172 fee code can be billed per day. Lack of clear 
consensus or guidelines has led to a deteriorating trend in 
this component of patient care over time. In general, the 
insurance carriers lack insight into the technical aspects 
of the FNA adequacy process to correct this detrimental 
trend. Publications such as the current commentary from 
the Economic and Government Affairs Committee of the 
ASC, published here in “open access” for easy access to the 
public including policy makers, are critical and healthy 
trends to address this issue before it gets worse. We applaud 
the Economic and Government Affairs Committee of 
ASC for their initiative in this matter by publishing their 
commentary in the public domain. 
It is important to note that the evaluation of different 
types of specimens by a variety of approaches also impacts 
the cost analysis. For example, performing pancreatic 
FNAs are more time consuming than performing FNAs 
of more easily accessible areas such as the thyroid, 
which requires a much longer time for onsite adequacy 
assessment with multiple passes.[11] It would be prudent 
that compensation for the onsite adequacy evaluation be 
adjusted with appropriate modifiers for the procedures 
that routinely require a longer time due to complexity 
such as with cytotechnologist (CT)-guided, ultrasound-
guided, bronchoscopic or endoscopic FNAs and other 
factors [Table 2]. Proper compensation would encourage 
pathologists to devote the time for this critical function 
and may spur innovation such as the application of 
telecytopathology for remote immediate adequacy 
assessment.[12,13]
evaluation of each pass of any FNA is analogous to the 
frozen sectioning scenario with deeper sections of the 
same frozen block as well as additional tissue from the 
same specimen submitted for frozen section. Professional 
time and skilled interpretations of complex pathological 
interpretations, whether on multiple frozen sections or 
multiple immediate interpretations of an FNA, should be 
appropriately compensated [Table 1].
It is widely accepted that immediate adequacy evaluation 
greatly reduces the cost of patient care.[5] Onsite 
adequacy evaluation also provides interactive real-time 
communication of information including appropriate 
tissue triage recommendations for ancillary tests such 
as flow cytometry, EM, cytogenetics, etc. This directly 
impacts clinical management during the critical diagnostic 
phase while the lesion can still be sampled readily.[6] Any 
compromise of this step will adversely affect the ultimate 
cost and quality of patient care [Figure 1]. Studies have 
reported the increase in diagnostic yield due to onsite 
adequacy evaluation with an obvious benefit to patient 
care [Figure 1].[7-10] Inability to provide onsite adequacy 
services would lead to increased cost due to an increased 
number of repeat procedures with resultant increase 
in patient morbidity and suboptimal care. Improper 
compensation practices disproportionate to the time and 
resource investment have already been pushing this service 
into disfavor by many pathology departments due to cost 
of providing this support.
Published literature criticizing the recent trends in 
compensation practices for the cytopathology services in 
this endeavor are relatively limited. In the study by Layfield 
et al, the time spent on various FNA adequacy evaluations 
was similar to that at Wayne State University Hospitals and 
ranged from 35 to 56 minutes with time cost exceeding 
compensation by $40-50 per procedure.[7] They concluded 
that intraprocedural consultations by the cytopathologist 
for onsite adequacy evaluation of FNA procedures are 
compensated insufficiently by the CPT code 88172 even 
with the use of a separate 88172 CPT code for each 
FNA pass and independent immediate interpretation. 
The payment may be adequate if the cytopathologist 
personally performs the aspirate with immediate onsite 
Table 1: Comparative reimbursement RVUs for onsite FNA adequacies, frozen section and touch prep.
CPT Code SERVICE Time RVU
88172 On site adequacy evaluation of FNA 35-56 min Carrier A
0.83
Carrier B
1.1
88331 First tissue block with frozen section(s) single specimen 10-20 min 1.7 2.2
88332 Each additional tissue block with frozen section(s) 10-20 min 0 .82 1.07
88333 Cytological examination (i.e. touch prep) First area 10-15 min 1.7 2.2
88334 Cytological examination (i.e. touch prep) Each additional area 10-15 min 1.02 1.4
RVU, Relative value unit; FNA, fine needle aspirate[4]
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Another issue of significance to be highlighted here is 
the role of the CT in onsite adequacy evaluation (not 
interpretation) under the supervision of the pathologist 
(who is available for consultation as needed). The CT has 
a definite role to play in the settings when pathologists 
are not available for onsite FNA services but can provide 
supervision with availability for direct input as indicated. 
In the current situation, 88172TC is not considered a 
stand-alone fee code without an associated 88172PC.[3] 
If a CT performs onsite adequacy under such conditions, 
Figure 1: Comparative scenario in the evolution of patient care involving FNA with onsite adequacy versus without onsite adequacy.
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evaluation support
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with
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it should be compensated by modified CPT 88172 
(higher compensation than 88172TC included in global 
component). The modified 88172 for example may be 
88172TC-ADQ [Table 2]. However, compensation for 
adequacy evaluations performed by CTs have different 
problems with additional ambiguity. Alsohaibani et al. 
showed that onsite FNA adequacy evaluation by CTs had 
an increased diagnostic yield compared with blind FNAs 
(77% versus 53%, respectively).[10] This approach would 
be a definite help in many institutions with limited 
availability of pathologists for onsite adequacy. The worst 
case scenario would be limitation or cessation of such 
services in the long run. Even in the academic settings with 
relatively less emphasis on the cost component due to the 
teaching value of the FNA adequacy exercise, currently 
there is an increasing reluctance to provide this support. 
A standard of practice across the board allowing separate 
billing for onsite adequacy of each pass of FNA is pivotal 
to prevent the potential debacle of this important service 
in patient care. This component is crucial for continued 
savings in overall patient care cost with better care and 
less morbidity. Given this fact, our clinical colleagues 
dependent on this support would agree that it is imperative 
that we proactively advocate the right approach. We 
look forward to the upcoming guidelines by the Center 
for Medical Services and strongly recommend that the 
cytopathology community let their voice be heard in the 
open public forum regarding this issue.
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Table 2: Hypothetical reimbursement for onsite FNA adequacies after considering complexities and 
time factor.
Onsite adequacy evaluation Nature of 
pass(es)
Suggested level of relative compensation code  
related to original CPT code of 88172 *
X
For adequacy 
by Cytopathologist/
cytopathology-trained 
pathologists
Y
For adequacy 
by Cytotechnologists with 
cytopathologist/cytopathology-
trained pathologists 
available for consultation
FNA of superficial lesions with average 
complexity and time requirement
First pass A. 88172- modifier 26 (Global) M. 88172 TC-ADQ
Additional 
pass(es)
B. 88172- with modifier 26/76 
(Global)
N. 88172 TC-ADQ with modifier ‘a’
FNA of deeper lesions under image 
guidance such as US guided thyroid 
FNA
First pass C. 88172- modifier 26+ (Global) O. 88172 TC-ADQ+
Additional 
pass(es)
D. 88172 with modifier 26/76+ 
(Global)
P. 88172 TC-ADQ + with modifier ‘a’
FNA of deeper lesions with complex 
procedures needing longer time, such 
as EUS-FNA, transbronchial FNA, 
intraoperative FNA
First pass E. 88172-modifier 26++ (Global) Q. 88172 TC-ADQ++
Additional 
pass(es)
F. 88172 with modifier 26/76++ 
(Global)
R. 88172 TC-ADQ++ with modifier ‘a’
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